- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06326047
Une étude de recherche comparant dans quelle mesure différentes doses du médicament NN0519-0130 réduisent la glycémie chez les personnes atteintes de diabète de type 2
Enquête sur l'innocuité et l'efficacité du NNC0519-0130 une fois par semaine chez les participants atteints de diabète de type 2 - une étude de recherche de dose
This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Free State
-
Bloemfontein, Free State, Afrique du Sud, 9301
- Josha Research
-
-
Gauteng
-
Johannesburg, Gauteng, Afrique du Sud, 2013
- Wits Bara Clinical Trial Site
-
Midrand, Gauteng, Afrique du Sud, 1685
- Dr A Jacovides and Partners Inc
-
-
KwaZulu-Natal
-
Durban, KwaZulu-Natal, Afrique du Sud, 4450
- Dr Pillay's Rooms
-
eMkhomazi, KwaZulu-Natal, Afrique du Sud, 4170
- Dr T Padayachee
-
-
-
-
New South Wales
-
Campbelltown, New South Wales, Australie, 2560
- Campbelltown Hospital
-
Macquarie Park, New South Wales, Australie, 2109
- Macquarie University - Clinical Trials Unit
-
St Leonards, New South Wales, Australie, 2065
- Royal North Shore Hospital
-
Sydney, New South Wales, Australie, 2148
- Western Endocrine Blacktown
-
Sydney, New South Wales, Australie, 2148
- Roger Chih Yu Chen
-
Wollongong, New South Wales, Australie, 2500
- Illawarra Diabetes Service Clinical Trials & Research Unit
-
-
Queensland
-
Birtinya, Queensland, Australie, 4575
- University of Sunshine Coast - Vitality Village
-
Meadowbrook, Queensland, Australie, 4131
- Logan Hospital
-
-
South Australia
-
Oaklands Park, South Australia, Australie, 5046
- Southern Adelaide Diabetes & Endocrine Services
-
-
Victoria
-
Box Hill, Victoria, Australie, 3128
- Eastern Clinical Research Unit Box Hill
-
Camberwell, Victoria, Australie, 3124
- Emeritus Research Melbourne
-
Heidelberg Heights, Victoria, Australie, 3081
- Austin Health, Metabolic Disorders Centre
-
Parkville, Victoria, Australie, 3050
- The Royal Melbourne Hospital
-
Parkville, Victoria, Australie, 3050
- The Royal Melbourne Hospital - Diabetes & Endocrinology Department
-
-
Western Australia
-
Fremantle, Western Australia, Australie, 6160
- Fremantle Hospital
-
-
-
-
-
Québec, Canada, G1V 4T3
- Diex Recherche Quebec
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1Y 1Z9
- OCT Research ULC (dba Okanagan Clinical Trials)
-
Richmond, British Columbia, Canada, V6V 2L1
- OCT Research ULC (dba Okanagan Clinical Trials)
-
Victoria, British Columbia, Canada, V8V 4A1
- Cook Street Medical Clinic
-
-
New Brunswick
-
Moncton, New Brunswick, Canada, E1G 1A7
- G.A. Research Associates Ltd.
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 1V7
- Nova Scotia Hlth Halifax
-
-
Ontario
-
Barrie, Ontario, Canada, L4N 7L3
- Centricity Research Barrie
-
Hamilton, Ontario, Canada, L8L 5G8
- Wharton Medical Clinic Clinical Trials (Hamilton)
-
Sarnia, Ontario, Canada, N7T 4X3
- London Road Diagnostic Clinic and Medical Centre
-
Toronto, Ontario, Canada, M4G 3E8
- Centricity Research Toronto
-
Toronto, Ontario, Canada, M9V 4B4
- Albion Finch Medical Centre
-
-
Quebec
-
Lévis, Quebec, Canada, G6W 0M5
- Centricity Research Quebec City
-
Mirabel, Quebec, Canada, J7J 2K8
- Centricity Research Mirabel
-
Montreal, Quebec, Canada, H1Y 3H5
- Recherche GCP Research
-
Saint-Laurent, Quebec, Canada, H4T 1Z9
- Centricity Research Ville St. Laurent VSL
-
-
-
-
-
Seoul, Corée du Sud, 05505
- Asan Medical Center
-
Seoul, Corée du Sud, 01830
- Nowon Eulji Medical Center, Eulji University
-
Seoul, Corée du Sud, 03181
- Kangbuk Samsung Hospital
-
Seoul, Corée du Sud, 02841
- Korea University Anam Hospital
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, Corée du Sud, 13620
- Seoul National University Bundang Hospital
-
-
-
-
-
Bengaluru, Inde, 560054
- MS Ramaiah
-
New Delhi, Inde, 110001
- Lady Hardinge Medical College
-
-
Karnataka
-
Bangalore, Karnataka, Inde, 560092
- Life Care Hospital and Research Centre
-
-
Kerala
-
Kochi, Kerala, Inde, 682041
- Amrita Institute Of Medical Sciences & Research Centre
-
-
Madhya Pradesh
-
Indore, Madhya Pradesh, Inde, 452010
- TOTALL Diabetes Hormone Institute
-
-
Maharashtra
-
Mumbai, Maharashtra, Inde, 400012
- Seth GS Medical College & KEM Hospital
-
Pune, Maharashtra, Inde, 411021
- Chellaram Diabetes Institute
-
-
Rajasthan
-
Jaipur, Rajasthan, Inde, 302006
- Diabetes, Thyroid and Endocrine Centre
-
-
Tamil Nadu
-
Vellore, Tamil Nadu, Inde, 632004
- Christian Medical College Hospital, Vellore
-
-
Telangana
-
Hyderabad, Telangana, Inde, 500082
- Diabetes Research Center, Hyderabad
-
-
-
-
-
Chiba, Japon, 261-0004
- Tokuyama clinic_Diabetic internal medicine
-
Soka-shi, Saitama, Japon, 340-0015
- Soka Sugiura Internal Medicine Clinic
-
Tokyo, Japon, 104-0031
- Fukuwa Clinic
-
Tokyo, Japon, 103-0027
- Tokyo-Eki Center-building Clinic_Internal Medicine
-
Tokyo, Japon, 104-0031
- Fukuwa Clinic_Internal Medicine
-
-
-
-
California
-
Chula Vista, California, États-Unis, 91911
- Velocity Clin Res-Chula Vista
-
Fresno, California, États-Unis, 93720
- Valley Research
-
Inglewood, California, États-Unis, 90301
- 310 Clinical Research
-
La Mesa, California, États-Unis, 91942
- Velocity Clin Res San Diego
-
Lancaster, California, États-Unis, 93534
- First Valley Med Grp Lancaster
-
Lomita, California, États-Unis, 90717
- Torrance Clin Res Inst, Inc.
-
Los Alamitos, California, États-Unis, 90720
- Pacific Clinical Studies
-
Los Angeles, California, États-Unis, 90057
- Velocity Clinical Research Westlake
-
Montclair, California, États-Unis, 91763
- Catalina Research Institute, LLC
-
San Diego, California, États-Unis, 92123
- Artemis Insitute for Clin Res
-
Toluca Lake, California, États-Unis, 91602
- Med Partners, Inc.
-
Torrance, California, États-Unis, 90505
- UCLA Health Southbay Endocrine
-
Tustin, California, États-Unis, 92780
- University Clin Investigators
-
Walnut Creek, California, États-Unis, 94598
- Diablo Clinical Research, Inc.
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80045
- University of Colorado Hospital
-
-
Florida
-
Clearwater, Florida, États-Unis, 33756
- Innovative Research of W Florida Inc.
-
Clearwater, Florida, États-Unis, 33756
- Innovative Research of W FL
-
Miami, Florida, États-Unis, 33183
- International Research Associates, LLC_Miami
-
-
Georgia
-
Columbus, Georgia, États-Unis, 31904
- Centricity Research
-
-
Idaho
-
Blackfoot, Idaho, États-Unis, 83221
- Elite Clinical Trials
-
-
Illinois
-
Peoria, Illinois, États-Unis, 61603
- Methodist Medical Center of Illinois
-
-
Iowa
-
Iowa City, Iowa, États-Unis, 52242
- University of Iowa
-
-
Maryland
-
Columbia, Maryland, États-Unis, 21045
- Centennial Medical Group
-
Oxon Hill, Maryland, États-Unis, 20745
- MD Medical Research
-
Rockville, Maryland, États-Unis, 20852
- Endo And Metab Cons
-
-
Missouri
-
Springfield, Missouri, États-Unis, 65807
- Clinvest Research
-
-
Montana
-
Butte, Montana, États-Unis, 59701
- Mercury Str Med Grp, PLLC
-
-
Nebraska
-
Lincoln, Nebraska, États-Unis, 68510
- Velocity Clinical Research Lincoln
-
-
Nevada
-
Las Vegas, Nevada, États-Unis, 89148
- Palm Research Center Inc-Vegas
-
Las Vegas, Nevada, États-Unis, 89109
- Excel Clinical Network
-
-
New York
-
Binghamton, New York, États-Unis, 13905
- Velocity Clinical Research Binghamton
-
-
North Carolina
-
Greensboro, North Carolina, États-Unis, 27408
- PharmQuest Life Sciences LLC
-
Wilmington, North Carolina, États-Unis, 28401
- Accellacare Wilmington
-
-
Ohio
-
Canton, Ohio, États-Unis, 44718
- Diab & Endo Assoc of Stark Co
-
Cincinnati, Ohio, États-Unis, 45242
- Velocity Clin Res_Cincinnati
-
Cincinnati, Ohio, États-Unis, 45246
- Velocity Clinical Research Springdale
-
Dayton, Ohio, États-Unis, 45439
- Providence Health Partners Ctr
-
Maumee, Ohio, États-Unis, 43537
- Advanced Med Res Maumee
-
-
Oregon
-
Grants Pass, Oregon, États-Unis, 97527
- Velocity Clin Res Grants Pass
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19114
- Tristar Clin Investigations, PC
-
Pittsburgh, Pennsylvania, États-Unis, 15243
- Preferred Primary Care Physicians Inc.
-
Uniontown, Pennsylvania, États-Unis, 15401
- Preferred Primary Care Physicians, Inc.
-
-
Texas
-
Abilene, Texas, États-Unis, 79606
- Velocity Clinical Research Abilene
-
Austin, Texas, États-Unis, 78759
- Velocity Clin Res Austin
-
Dallas, Texas, États-Unis, 75390
- UT Southwestern Med Center
-
Dallas, Texas, États-Unis, 75230
- Velocity Clinical Res-Dallas
-
Dallas, Texas, États-Unis, 75230
- Zenos Clinical research
-
Forney, Texas, États-Unis, 75126
- Care United Research, LLC
-
Houston, Texas, États-Unis, 77004
- Endocrine Associates Houston
-
Houston, Texas, États-Unis, 77043
- Biopharma Informatic_Houston
-
Irving, Texas, États-Unis, 75039
- Tekton Research
-
Lewisville, Texas, États-Unis, 75057
- Epic Clinical Research
-
Shavano Park, Texas, États-Unis, 78231
- Consano Clinical Research, LLC
-
-
Virginia
-
Burke, Virginia, États-Unis, 22015
- Burke Internal Medicine & Research
-
Newport News, Virginia, États-Unis, 23606
- TPMG Clinical Research
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Female of non-childbearing potential, or male.
- For United States (US) only: Female of childbearing potential using highly effective non-systemic methods of contraception with low user-dependency and willingness to continue using it through-out the study or male.
- Age 18-75 years (both inclusive) at the time of signing the informed consent.
- Diagnosed with type 2 diabetes mellitus greater than or equal 180 days before screening.
- Stable daily dose(s) more than or equal 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without sodium-glucose co-transporter 2 (SGLT2) inhibitor.
- Glycated haemoglobin (HbA1c) of 7.5-10.0% (58-86 millimoles per moles (mmol/mol)) (both inclusive) as assessed by central laboratory at screening.
- Body mass index (BMI) greater than or equal 23.0 kilograms per meter square (kg/m^2).
Exclusion Criteria:
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
- Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Dosing scheme A (NNC0519-0130)
Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as subcutaneous (s.c.) injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Comparateur placebo: Dosing scheme A (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Expérimental: Dosing scheme B (NNC0519-0130)
Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Comparateur placebo: Dosing scheme B (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Expérimental: Dosing scheme C (NNC0519-0130)
Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Comparateur placebo: Dosing scheme C (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Expérimental: Dosing scheme D (NNC0519-0130)
Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Comparateur placebo: Dosing scheme D (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Expérimental: Dosing scheme E (NNC0519-0130)
Participants will receive NNC0519-0130 at 7 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Comparateur placebo: Dosing scheme E (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Comparateur actif: Dosing scheme F (tirzepatide)
Participants will receive tirzepatide at 6 dose levels once weekly as s.c. injection in dose escalating manner. |
Trizepatide will be administered subcutaneously. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Glycated haemoglobin (HbA1c)
Délai: From baseline (week 0) to 12 weeks on a given maintenance dose
|
Measured as percentage point (%-point) |
From baseline (week 0) to 12 weeks on a given maintenance dose
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Glycated haemoglobin (HbA1c)
Délai: From baseline (week 0) to end of treatment (week 36)
|
Measured as percentage point (%-point) |
From baseline (week 0) to end of treatment (week 36)
|
|
Relative change in body weight
Délai: From baseline (week 0) to end of treatment (week 36)
|
Measured as percentage (%) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in body weight
Délai: From baseline (week 0) to end of treatment (week 36)
|
Measured as kilograms (kg) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in fasting plasma glucose (FPG)
Délai: From baseline (week 0) to 12 weeks on a given maintenance dose
|
Measured as millimoles per liter (mmol/L) |
From baseline (week 0) to 12 weeks on a given maintenance dose
|
|
Continuous glucose monitoring (CGM): Change in time in range (TIR) 3.9-10.0 millimoles per liter (mmol/L) (70-180 milligrams per deciliter (mg/dL))
Délai: From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively
|
Measured as percentage point (%-point) |
From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively
|
|
Change in waist circumference
Délai: From baseline (week 0) to end of treatment (week 36)
|
Measured as centimeter (cm) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in systolic blood pressure (SBP)
Délai: From baseline (week 0) to end of treatment (week 36)
|
Measured as millimeters of mercury (mmHg) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high sensitivity C-Reactive Protein (hsCRP)
Délai: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in total cholesterol
Délai: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high-density lipoprotein (HDL) cholesterol
Délai: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in low-density lipoprotein (LDL) cholesterol
Délai: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in triglycerides
Délai: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Number of adverse events
Délai: From baseline (week 0) to end of study (week 40)
|
Measured as number of events |
From baseline (week 0) to end of study (week 40)
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- NN9541-4945
- U1111-1291-9196 (Autre identifiant: World Health Organization (WHO))
- jRCT2031230704 (Identificateur de registre: JRCT)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .